Jaguar Health Inc (JAGX)

Currency in USD
2.1200
-0.1500(-6.61%)
Closed·
2.0300-0.0900(-4.25%)
·
JAGX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.05002.3000
52 wk Range
1.570133.2500
Key Statistics
Prev. Close
2.12
Open
2.26
Day's Range
2.05-2.3
52 wk Range
1.5701-33.25
Volume
117.87K
Average Volume (3m)
150.12K
1-Year Change
-93.11%
Book Value / Share
4.15
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
JAGX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
25.5000
Upside
+1,102.83%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Jaguar Health Inc News & Analysis

Show more

Jaguar Health Inc Company Profile

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

Employees
49

Jaguar Health Inc Earnings Call Summary for Q2/2025

  • Q2 2025 net revenue up 35% to $3M, but stock tumbles 14.67% to $2.21 in premarket trading
  • Net loss widens to $10.4M from $9.5M YoY; operational losses increase amid product development efforts
  • Crofelemer drug advancing for multiple indications, including cancer therapy-related diarrhea
  • CEO highlights 2025 as 'year of convergence' for clinical and regulatory catalysts
  • Company seeks partnerships for non-dilutive funding; faces profitability challenges and high debt burden
Last Updated: 14/08/2025, 14:26
Read Full Transcript

Compare JAGX to Peers and Sector

Metrics to compare
JAGX
Peers
Sector
Relationship
P/E Ratio
−0.4x−2.9x−0.7x
PEG Ratio
−0.04−0.120.00
Price/Book
3.0x0.0x2.6x
Price / LTM Sales
1.4x0.7x3.4x
Upside (Analyst Target)
-16.5%37.6%
Fair Value Upside
Unlock19.1%5.3%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 25.5000
(+1,102.83% Upside)

Earnings

Latest Release
Aug 14, 2025
EPS / Forecast
-10.26 / -0.28
Revenue / Forecast
2.98M / 5.74M
EPS Revisions
Last 90 days

JAGX Income Statement

People Also Watch

0.614
PSTV
-9.71%
1.820
DVLT
-13.33%
32.44
WOLF
+0.03%
1.670
CAN
-14.80%
1.3300
DFLI
-32.49%

FAQ

What Stock Exchange Does Jaguar Health Trade On?

Jaguar Health is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Jaguar Health?

The stock symbol for Jaguar Health is "JAGX."

What Is the Jaguar Health Market Cap?

As of today, Jaguar Health market cap is 16.33M.

What Is Jaguar Health's Earnings Per Share (TTM)?

The Jaguar Health EPS (TTM) is -26.56.

From a Technical Analysis Perspective, Is JAGX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Jaguar Health Stock Split?

Jaguar Health has split 6 times.

How Many Employees Does Jaguar Health Have?

Jaguar Health has 49 employees.

What is the current trading status of Jaguar Health (JAGX)?

As of 17 Oct 2025, Jaguar Health (JAGX) is trading at a price of 2.1200, with a previous close of 2.12. The stock has fluctuated within a day range of 2.0500 to 2.3000, while its 52-week range spans from 1.5701 to 33.2500.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.